kneat.com Valuation

Is KSI undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of KSI when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: KSI (CA$4.54) is trading above our estimate of fair value (CA$1.66)

Significantly Below Fair Value: KSI is trading above our estimate of fair value.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for KSI?

Other financial metrics that can be useful for relative valuation.

KSI key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue9.4x
Enterprise Value/EBITDA-34.9x
PEG Ration/a

Price to Sales Ratio vs Peers

How does KSI's PS Ratio compare to its peers?

The above table shows the PS ratio for KSI vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average4.5x
VHI Vitalhub
7.8x13.5%CA$456.3m
RHT Reliq Health Technologies
3.2xn/aCA$47.3m
CDX.H Cloud DX
6.2xn/aCA$12.1m
CRBK Carebook Technologies
0.5xn/aCA$7.7m
KSI kneat.com
9.6x27.2%CA$390.2m

Price-To-Sales vs Peers: KSI is expensive based on its Price-To-Sales Ratio (9.6x) compared to the peer average (4.5x).


Price to Earnings Ratio vs Industry

How does KSI's PE Ratio compare vs other companies in the CA Healthcare Services Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a31.9%
n/an/an/a
No. of CompaniesPS048121620

Fetching data

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a31.9%
n/an/an/a
No more companies

Price-To-Sales vs Industry: KSI is expensive based on its Price-To-Sales Ratio (9.6x) compared to the North American Healthcare Services industry average (3.1x).


Price to Sales Ratio vs Fair Ratio

What is KSI's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

KSI PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio9.6x
Fair PS Ratio7.7x

Price-To-Sales vs Fair Ratio: KSI is expensive based on its Price-To-Sales Ratio (9.6x) compared to the estimated Fair Price-To-Sales Ratio (7.7x).


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst KSI forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentCA$4.54
CA$5.31
+16.9%
5.7%CA$5.75CA$4.90n/a6
Sep ’25CA$5.04
CA$5.31
+5.3%
5.7%CA$5.75CA$4.90n/a6
Aug ’25CA$4.50
CA$5.06
+12.4%
7.4%CA$5.75CA$4.50n/a6
Jul ’25CA$4.24
CA$5.06
+19.3%
7.4%CA$5.75CA$4.50n/a6
Jun ’25CA$4.30
CA$4.93
+14.7%
10.3%CA$5.75CA$4.15n/a6
May ’25CA$3.85
CA$4.36
+13.2%
9.3%CA$5.00CA$3.70n/a6
Apr ’25CA$3.67
CA$4.36
+18.8%
9.3%CA$5.00CA$3.70n/a6
Mar ’25CA$3.70
CA$4.36
+17.8%
9.3%CA$5.00CA$3.70n/a6
Feb ’25CA$3.45
CA$4.11
+19.1%
7.8%CA$4.50CA$3.70n/a6
Jan ’25CA$3.05
CA$4.11
+34.7%
7.8%CA$4.50CA$3.70n/a6
Dec ’24CA$3.15
CA$4.11
+30.4%
7.8%CA$4.50CA$3.70n/a6
Nov ’24CA$2.72
CA$4.15
+52.6%
9.2%CA$4.75CA$3.70n/a6
Oct ’24CA$3.04
CA$4.15
+36.5%
9.2%CA$4.75CA$3.70CA$4.646
Sep ’24CA$3.07
CA$4.15
+35.2%
9.2%CA$4.75CA$3.70CA$5.046
Aug ’24CA$3.27
CA$4.19
+28.2%
10.8%CA$5.00CA$3.70CA$4.506
Jun ’24CA$2.65
CA$4.19
+58.2%
10.8%CA$5.00CA$3.70CA$4.306
May ’24CA$2.49
CA$4.19
+68.3%
10.8%CA$5.00CA$3.70CA$3.856
Apr ’24CA$2.60
CA$4.07
+56.4%
6.9%CA$4.50CA$3.70CA$3.676
Mar ’24CA$2.79
CA$4.07
+45.8%
6.9%CA$4.50CA$3.70CA$3.706
Feb ’24CA$2.99
CA$3.98
+33.2%
7.3%CA$4.50CA$3.70CA$3.456
Jan ’24CA$2.67
CA$3.98
+49.2%
7.3%CA$4.50CA$3.70CA$3.056
Dec ’23CA$2.69
CA$3.98
+48.1%
7.3%CA$4.50CA$3.70CA$3.156
Nov ’23CA$2.60
CA$4.02
+54.5%
8.0%CA$4.50CA$3.70CA$2.726
Oct ’23CA$2.47
CA$4.02
+62.6%
8.0%CA$4.50CA$3.70CA$3.046

Analyst Forecast: Target price is less than 20% higher than the current share price.


Discover undervalued companies